Đang chuẩn bị liên kết để tải về tài liệu:
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: A meta-analysis

The first-generation epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib have both been proven effective for treating advanced non–small cell lung cancer (NSCLC), especially in East Asian patients. | Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non small cell lung cancer A meta-analysis